Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Recommendations of the European League Against Rheumatism (EULAR) for the treatment of "large-vessel vasculitides"].

× No keyword cloud information.

12 in total

1. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.

Authors: F Cantini; L Niccoli; C Salvarani; A Padula; I Olivieri
Journal: Arthritis Rheum Date: 2001-12

2. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.

Authors: G G Hunder; S G Sheps; G L Allen; J W Joyce
Journal: Ann Intern Med Date: 1975-05 Impact factor: 25.391

3. EULAR recommendations for the management of large vessel vasculitis.

Authors: C Mukhtyar; L Guillevin; M C Cid; B Dasgupta; K de Groot; W Gross; T Hauser; B Hellmich; D Jayne; C G M Kallenberg; P A Merkel; H Raspe; C Salvarani; D G I Scott; C Stegeman; R Watts; K Westman; J Witter; H Yazici; R Luqmani
Journal: Ann Rheum Dis Date: 2008-04-15 Impact factor: 19.103

4. Meta-analysis: test performance of ultrasonography for giant-cell arteritis.

Authors: Fotini B Karassa; Miltiadis I Matsagas; Wolfgang A Schmidt; John P A Ioannidis
Journal: Ann Intern Med Date: 2005-03-01 Impact factor: 25.391

5. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Authors: Gary S Hoffman; Maria C Cid; Karen E Rendt-Zagar; Peter A Merkel; Cornelia M Weyand; John H Stone; Carlo Salvarani; Weichun Xu; Sudha Visvanathan; Mahboob U Rahman
Journal: Ann Intern Med Date: 2007-05-01 Impact factor: 25.391

6. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.

Authors: Anne Proven; Sherine E Gabriel; Carlos Orces; W Michael O'Fallon; Gene G Hunder
Journal: Arthritis Rheum Date: 2003-10-15

7. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.

Authors: Gary S Hoffman; Peter A Merkel; Richard D Brasington; Deborah J Lenschow; Patrick Liang
Journal: Arthritis Rheum Date: 2004-07

8. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis.

Authors: M Both; K Ahmadi-Simab; M Reuter; O Dourvos; E Fritzer; S Ullrich; W L Gross; M Heller; M Bähre
Journal: Ann Rheum Dis Date: 2008-01-26 Impact factor: 19.103

9. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients.

Authors: Ana García-Martínez; José Hernández-Rodríguez; Pedro Arguis; Pilar Paredes; Marta Segarra; Ester Lozano; Carlos Nicolau; José Ramírez; Francesc Lomeña; Miguel Josa; Francesca Pons; Maria C Cid
Journal: Arthritis Rheum Date: 2008-03-15

10. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.

Authors: V M Martínez-Taboada; V Rodríguez-Valverde; L Carreño; J López-Longo; M Figueroa; J Belzunegui; E M Mola; G Bonilla
Journal: Ann Rheum Dis Date: 2007-12-17 Impact factor: 19.103

1 in total

Review 1. [Imaging techniques in the evaluation of primary large vessel vasculitides: part 1: angiography, interventional therapy, and magnetic resonance imaging].

Authors: M Both; B Nölle; C von Forstner; F Moosig; W L Gross; M Heller
Journal: Z Rheumatol Date: 2009-08 Impact factor: 1.372

1 in total